With growing interest in developing therapeutics to mitigate neuroinflammation in AD, antibody-based PET radioligands targeting TREM2 present a promising alternative to the aforementioned small-molecule radioligands for visualizing activated microglia. The gene discussed is TREM2; the disease is Alzheimer disease.